Metraipolis › archive › dc_fabca84497c1

Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study — Europe PMC PMID:41536940

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41536940
DOI
10.1016/j.eclinm.2025.103717
License (as archived)
solo-consultazione
Archived
2026-11-07T09:11:49.197Z
SHA-256 of the archived text
c680e44568fa1ce26e4f5b0c583933d4df037e29ae8bcb7c9155030da7e45a11
Stable URL of this page
https://metraipolis.com/documento/dc_fabca84497c1

How to cite

Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study — Europe PMC PMID:41536940 — Europe PMC (en), https://europepmc.org/article/MED/41536940 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fabca84497c1 (Metraipolis archive dc_fabca84497c1, sha256 c680e44568fa1ce26e4f5b0c583933d4df037e29ae8bcb7c9155030da7e45a11)
BibTeX
@misc{dcfabca84497c1,
  title = {Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study — Europe PMC PMID:41536940},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41536940},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fabca84497c1; sha256 c680e44568fa1ce26e4f5b0c583933d4df037e29ae8bcb7c9155030da7e45a11},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41536940. Agents can read the archived copy with the MCP tool read_document.